Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal
Shelby Knowles / Bloomberg / Getty Images Eli Lilly shares have added over a third of their value…
Lilly cuts price for obesity drug Zepbound
Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…
Ozempic Prices Lowered After Trump Deal
Topline Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment…
Novo cuts Wegovy prices, Zepbound cost also coming down
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients…
Eli Lilly, Tan France launch Zepbound ‘Changing the Thread’
New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS, Nov. 10,…
Mounjaro mounts to top spot in Indian drug market; Oct sales touch ₹100 cr, ETPharma
New Delhi: Maintaining its growth momentum for the seventh straight month, Eli Lilly’s type-2 diabetes and weight-loss drug…
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
By Mrinalika Roy and Patrick Wingrove (Reuters) -Eli Lilly said on Thursday its experimental weight-loss pill met most…
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechanger
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President…
LLY’s Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 pill, in…
Wall Street rises to its first gain in 4 days
NEW YORK (AP) — U.S. stocks climbed Friday and trimmed their losses for the week after a report…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…